Delcath Systems Inc. (DCTH)
12.05
0.09 (0.75%)
At close: Apr 24, 2025, 3:59 PM
0.75% (1D)
| Bid | 11.25 |
| Market Cap | 402.86M |
| Revenue (ttm) | 35.56M |
| Net Income (ttm) | -26.39M |
| EPS (ttm) | -0.93 |
| PE Ratio (ttm) | -12.96 |
| Forward PE | 16.41 |
| Analyst | Strong Buy |
| Ask | 15 |
| Volume | 354,977 |
| Avg. Volume (20D) | 420,226 |
| Open | 12.11 |
| Previous Close | 11.96 |
| Day's Range | 11.76 - 12.21 |
| 52-Week Range | 5.04 - 16.97 |
| Beta | 0.85 |
About DCTH
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial fo...
Industry Medical - Specialties
Sector Healthcare
IPO Date May 3, 2018
Employees 96
Stock Exchange NASDAQ
Ticker Symbol DCTH
Website https://www.delcath.com
Analyst Forecast
According to 4 analyst ratings, the average rating for DCTH stock is "Strong Buy." The 12-month stock price forecast is $22.5, which is an increase of 86.72% from the latest price.
Stock ForecastsNext Earnings Release
Delcath Systems Inc. is scheduled to release its earnings on May 13, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-1.56%
Delcath Systems shares are trading lower after the...
Unlock content with
Pro Subscription
3 months ago
+11.41%
Delcath Systems shares are trading higher after the company announced Q4 revenue results.
